Our results highlight the effects of trastuzumab (herceptin) and fulvestrant (falsodex) as single agents or in combination on the cell proliferation rates of HR+/HER2+ human breast cancer cell lines ZR-75-1 and BT-474. Here, ERBB2 is linked to breast carcinoma.